Retatrutide
Retatrutide
A triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly as the next-generation obesity medication.
Typical Cost
Not yet priced (expected $1000-1500/month)
Status
Research
Peptide Profile
Retatrutide
Mechanism of Action
Activates GLP-1 receptors (appetite suppression), GIP receptors (enhanced insulin secretion), and glucagon receptors (increased energy expenditure). The first triple agonist for weight management.
Common Dosages
subcutaneous
1-12mg
Weekly · Ongoing
Benefits
Superior weight loss (24%+ in trials)
Improved glycemic control
Increased energy expenditure
Better lipid profiles
Cardiovascular benefits
Side Effects
Nausea
Vomiting
Diarrhea
Constipation
Injection site reactions
Gallbladder issues
Key Research
Retatrutide phase II trial
Average 24.2% weight loss at 48 weeks with 12mg dose, highest ever reported for obesity drug
Regulatory Status
Phase III clinical trials. Not yet FDA-approved. Fast-track designation granted.
Contraindications
- ⚠Medullary thyroid carcinoma history
- ⚠MEN2 syndrome
- ⚠Pregnancy/breastfeeding
- ⚠Personal/family history of pancreatitis
As the most potent obesity medication in development, retatrutide users will need robust side effect management. SeraVia Gut+ Balance and Muscle+ Protect will be essential supports.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.